HIV Integrase

HIV Integrase Full Name

human immunodeficiency virus 1 integrase

HIV Integrase Introduction

Research on HIV integrase (HIV Integrase) demonstrates that this enzyme is a critical catalytic component in the viral replication cycle, primarily responsible for integrating viral DNA into the host genome, thereby enabling persistent infection. Structurally, integrase consists of three domains: the N-terminal domain, the catalytic core domain (CCD), and the C-terminal domain. Among these, the CCD serves as the functional hub, catalyzing 3′-processing and strand transfer reactions. Its active site is typically composed of highly conserved residues that coordinate metal ions and facilitate DNA binding. The C-terminal domain mainly contributes to nonspecific DNA binding, while the N-terminal domain is involved in multimerization, together ensuring structural stability and enzymatic activity. In addition to the viral enzyme itself, host factors play essential roles in the integration process. LEDGF/p75 is recognized as a key integration cofactor that binds integrase and directs viral DNA toward transcriptionally active chromatin regions, thereby influencing integration site selection and infection efficiency. Other host proteins, such as TNPO3, contribute to nuclear import and maturation of the pre-integration complex, adding further layers of regulation.

From a drug development perspective, HIV integrase has become a major target for antiviral therapy. A wide range of integrase inhibitors with diverse chemical scaffolds has been identified, including diketo acids, caffeic acid derivatives, salicylhydrazines, indole-based compounds, and dinucleotide mimetics. These inhibitors act through multiple mechanisms, such as chelating metal ions in the active site, occupying DNA-binding interfaces, or mimicking substrate structures to disrupt enzymatic function. As a result, they effectively block either the 3′-processing step or the strand transfer reaction. Some compounds exhibit high-affinity or even irreversible binding, enhancing their inhibitory potency. Beyond direct inhibition of integrase catalytic activity, alternative strategies targeting the interaction between integrase and host factors—particularly the LEDGF/p75–integrase interface—have gained increasing attention. Such approaches may alter integration targeting or reduce integration efficiency, offering additional therapeutic avenues.

However, the widespread use of integrase inhibitors has led to the emergence of drug resistance. Studies show that single-point mutations within the integrase core domain can significantly reduce drug binding while preserving partial enzymatic activity, ultimately compromising treatment efficacy. Moreover, natural genetic variation and co-variation patterns among different HIV subtypes can influence resistance pathways and drug susceptibility, adding complexity to clinical management. Therefore, future research on HIV integrase should focus on developing inhibitors with novel mechanisms of action and improved pharmacokinetic profiles to overcome resistance. At the same time, continuous surveillance of viral diversity and integration of genotype–phenotype data will be essential for optimizing personalized treatment strategies. The intricate interplay between integrase structure, host cofactors, and inhibitor chemistry will continue to guide the development of more effective and durable anti-HIV therapies.

Alternate Names for HIV Integrase

HIV; Human Immunodeficiency virus 1; IN; Integrase; HIV1 integrase

• 1. Astiazaran P., et al. HIV-1 integrase modulates the interaction of the HIV-1 cellular cofactor LEDGF/p75 with chromatin. Retrovirology. 2011;8(1).
  2. Engelman A., et al. Cellular and molecular mechanisms of HIV-1 integration targeting. Cellular and Molecular Life Sciences. 2018;75(14):2491-2507.
  3. Larguet F., et al. Histone deacetylase 1 interacts with HIV-1 Integrase and modulates viral replication. Virology Journal. 2019;16(1).
  4. Wang Y., et al. The Discovery of Indole-2-carboxylic Acid Derivatives as Novel HIV-1 Integrase Strand Transfer Inhibitors. Molecules. 2023;28(24):8020.